ArticleJournal of ovarian research2025
SORCS2 serves as a tumor suppressor and associates with immune infiltration in ovarian cancer.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundOvarian cancer (OC) is a highly aggressive gynecological malignancy, with a poor 5-year survival rate of less than 50%. Identifying novel biomarkers and therapeutic targets is crucial to improving patient prognosis. Sortilin-related VPS10 domain-containing receptor 2 (SORCS2) regulates various biological processes and is implicated in carcinogenesis, yet its specific role in OC remains unclear. MATERIALS AND
methodsMultiple bio-informatics analyses were used to analyze SORCS2 expression and potential role in OC. Cell proliferation, migration assays and flow cytometry were performed to assess the effects of SORCS2 on OC cells. Further, Xenograft mouse models were built to identify its function in OC cell growth in vivo.
resultsIn this study, we first identified that SORCS2 expression is down-regulated in OC tissues, correlating with adverse clinical characteristics and poor clinical outcomes, emphasizing its potential as a prognostic marker for OC. In vitro, SORCS2 over-expression suppressed cell proliferation and migration, induced cell cycle arrest at the S/G2 phase via the p21/CCNA1 pathway, and induced apoptosis by regulating PIDD1 and CASP9. Xenograft mouse models further validated the tumor-suppressive effects of SORCS2 in vivo. Additionally, SORCS2 was found to participate in tumor-specific immune responses by promoting T cell activation and release of immune factors.
conclusionOur findings underscore SORCS2 as a tumor suppressor in OC development and highlight its potential as a prognostic marker for OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.